



**CANNABINOID**  
conference 2017

IACM 9<sup>th</sup> Conference on Cannabinoids in Medicine  
Maritim Hotel Cologne, Germany, 29-30 September 2017

<http://cannabinoidconference2017.org>

## Program

Last update: 08 May 2017

## Friday, September 29

08:00 - 17:00		Registration
		Presentation
09:00 - 09:40	Where do we stand?	Session I: Accepted medical uses and medications Donald Abrams: "Cannabis-based medicines: an introductory overview of all the major clinically relevant known knowns and known unknowns"
09:40 – 10:20 10:20 – 11:00		Ryan Vandrey: "Results of new human studies on cannabis" Kirsten Müller-Vahl: "Current cannabis-based medicines: a clinician's perspective"
11:00 – 11:15		Break
11:15 – 11:30 11:30 – 11:45 11:45 – 12:00 12:00 – 12:15 12:15 – 12:30		Submitted talk Submitted talk Submitted talk Submitted talk Submitted talk

12:30 – 13:00		Questions from a panel of experts: “What information do patients and their clinicians need?”
13:00 – 15:00		Lunch and <b>poster session 1</b>
15:00 – 15:40		<b>Session II: Genetics, strains and quality</b> <u>Ethan Russo</u> : “Chemovars (and a comparison of sativa & indica)”
15:40 – 16:20		<u>Jahan Marcu</u> : “Nature, variability & safety of marketed cannabis (NB pesticides) & how to optimize the safety & medical efficacy of marketed cannabis”
16:20 - 16:35		Break
16:35 – 17:05		<b>Session III: Laws and politics</b> <u>Mark Ware</u> : “Impact of new regulations on medical and recreational cannabis”
17:05 – 17:20		<u>Jeffrey Hergenrather</u> : “Country report: USA”
17:20 – 17:35		<u>Ilija Reznik</u> : “Country report: Israel”
17:35 – 17:50		<u>Franjo Grotenhermen</u> : “Country report: Germany”
17:50 – 18:05		<u>Sébastien Béguerie</u> : “Country report: France”
18:05 – 18:35		Questions from a panel of experts: “What are the best (and worst) ways forward for patients and their clinicians?”
19:00 – 22:00		<b>Dinner of IACM partner organizations and ambassadors</b>

## Saturday, September 30

<b>08:15 - 12:00</b>		<b>Registration</b>
		Presentation
09:00 – 09:40	<b>Where do we go?</b>	<b>Session IV: Emerging new indications</b> <u>Jonathan Page</u> : “Future exploitation of phytocannabinoids in the clinic - most promising future directions”

09:40 – 10:20		<u>Roger Pertwee</u> : “Future exploitation in the clinic of the endocannabinoid system and of synthetic drugs - most promising future directions”
10:20 – 11:00		<u>Daniele Piomelli</u> : “The future of cannabis-based medicines: a pharmacologist's perspective”
11:00 – 11:15		Break
11:15 – 11:55		<u>Guillermo Velasco</u> : “Promising future directions: cannabinoid medicines versus cancer”
11:55 – 12:10		Submitted talk
12:10 – 12:25		Submitted talk
12:25 – 12:40		Submitted talk
12:40 – 12:55		Submitted talk
12:55 – 15:00		Lunch and <b>poster session 2</b>
		<b>Session V: Knowledge and education</b>
15:00 – 15:40		<u>Franjo Grotenhermen</u> : “Promising indications with limited clinical evidence”
15:40 – 16:20		<u>Raquel Peyraube</u> : “What questions do clinicians and patients have on a treatment with cannabis-based medicines?”
16:20 – 17:00		Questions from a panel of experts: “What should clinicians, patients and regulators know? What questions are still waiting for an answer?”
17:00 – 17:15		Break
17:15 – 18:30		<b>IACM General Meeting</b>
19:00 – 22:00		<b>Dinner with Award Ceremony</b>

### Special thanks

Special thanks by the IACM Board of Directors go to our platin sponsor Bedrocan ([www.bedrocan.com](http://www.bedrocan.com)) for their extraordinary contribution to the conference to allow us to invite the best speakers for every topic and make this program possible.